James Baker-Knight

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 5

Top Topics

Body Mass Index

Multiple Sclerosis

Placebo Controlled

Top Venues

Obesity (Silver Spring, Md.)

Diabetes, obesity & metabolism

The Journal of clinical endocrinology and metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Barbara M McGowan, Azadeh Houshmand-Oeregaard, Peter Nørkjaer Laursen, Niels Zeuthen, James Baker-Knight
Impact of BMI and comorbidities on efficacy of once-weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial. Obesity (Silver Spring, Md.) (2023)
Barbara M McGowan, Azadeh Houshmand-Oeregaard, Peter Nørkjaer Laursen, Niels Zeuthen, James Baker-Knight
Impact of BMI and comorbidities on efficacy of once-weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial. Obesity (Silver Spring, Md.) 31 (4) (2023)
Barbara M McGowan, Azadeh Houshmand-Oeregaard, Peter Nørkjaer Laursen, Niels Zeuthen, James Baker-Knight
Impact of BMI and comorbidities on efficacy of once-weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial. Obesity (Silver Spring, Md.) 31 (4) (2023)
Ildiko Lingvay, Robert Bauer, James Baker-Knight, Jack Lawson, Richard E Pratley
An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression. The Journal of clinical endocrinology and metabolism 107 (5) (2022)
Nikolaos Kotsopoulos, Mark P Connolly, Michael Willis, Andreas Nilsson, Åsa Ericsson, James Baker-Knight
The public economic burden of suboptimal type 2 diabetes control upon taxpayers in Sweden: Looking beyond health costs. Diabetes, obesity & metabolism 24 (6) (2022)